Sphingosine-1-phosphate receptor 1 (S1P 1 ) modulators sequester circulating lymphocytes within lymph nodes, thereby preventing potentially pathogenic autoimmune cells from exiting into the blood stream and reaching inflamed tissues. S1P 1 receptor modulation may thus offer potential to treat various autoimmune diseases.
pathways contribute to the functional selectivity. The S1P 1 receptor is highly expressed in endothelial cells and it is the predominant S1P receptor subtype expressed in lymphocytes. Brain-specific expression was shown for the S1P 5 receptor, whereas S1P 4 receptor expression is limited to the immune system. S1P 2 and S1P 3 receptors are widely expressed and were shown to be involved in cardiovascular and lung physiology. 1 The concentration of S1P in blood is high, approximately 1 lmolÁL -1 , and it is much lower in tissues. It is believed that lymphocytes, through activation of S1P 1 receptors, migrate along a natural S1P gradient to exit secondary lymphoid tissue or thymus and enter the blood circulation. The nonselective S1P [1] [2] [3] [4] [5] receptor agonist FTY720 is a prodrug that is converted by sphingosine kinase into the phosphorylated bioactive form, pFTY720. In lymphocytes, pFTY720 promotes S1P 1 receptor activation, leading to sustained internalization and desensitization. 1, 2 This process renders the S1P 1 receptor functionally inactive, thereby trapping lymphocytes in secondary lymphoid organs. Experiments conducted in various animal models of autoimmune disease have demonstrated efficacy of S1P 1 receptor modulators across several immune-mediated chronic inflammatory conditions. 3 FTY720 (Fingolimod/Gilenya â ) became the first approved oral therapy for treatment of relapsing forms of multiple sclerosis. 4 In rodents, S1P 3 receptor agonism was associated with a reduction of heart rate by activation of G protein-coupled inwardly rectifying potassium channels (GIRK) that regulate pacemaker frequency, shape, and duration of action potentials. 5,6 S1P 3 receptor activation was also shown to mediate S1P-induced coronary and cerebral vasoconstriction. 7, 8 Furthermore, S1P 2 and S1P 3 receptor signaling stimulated extracellular matrix synthesis in human lung fibroblasts 9 and FTY720-induced pathological lung fibrosis findings were reported in dogs and monkeys. 10 S1P augments agonist-induced contraction of isolated mouse bronchial smooth muscle cells, 11 isolated mouse bronchi, and isolated mouse whole lung. 12 S1P levels were increased in asthmatic patients upon segmental allergen challenge 13 and S1P 2 receptor signaling induced smooth muscle cell contraction. 14, 15 This suggests that S1P signaling is involved in homeostatic control of airway physiology. Indeed, bronchoconstriction, as measured by a reduction in mean forced expiratory volume in 1 second (FEV1), was identified as a drug-related side-effect in the clinical use of FTY720. 4 In summary, these observations suggest that nonselective S1P receptor agonism, exemplified by FTY720, is associated with side-effects, which can be mitigated with improved S1P 1 receptor modulators.
In the present study, we describe cenerimod, a novel, selective and orally available S1P 1 receptor modulator that displays biased S1P 1 receptor signaling. We show that cenerimod induced potent blood lymphocyte count reduction in vivo and attenuated disease in a mouse experimental autoimmune encephalomyelitis (EAE) model.
Cenerimod was also shown to lack bronchoconstrictive and vasoconstrictive effects ex vivo and in vivo. The data presented here show that cenerimod has unique S1P 1 receptor signaling properties with a beneficial safety profile, encouraging further evaluation in human clinical trials targeting autoimmune diseases.
| MATERIALS AND METHODS

| Ethics statement
All experimental procedures were conducted in accordance with the Swiss animal welfare ordinance and Actelion Animal Welfare policy on the use of experimental animals. The studies were approved by the Baselland Cantonal Veterinary Home Office. The number of animals was kept to a strict minimum.
| Compounds
Sphingosine-1-phosphate (S1P) was purchased from Avanti Polar Lipids Inc. (USA). FTY720 and pFTY720 were purchased from commercial vendors. Siponimod, p-amiselimod, TASP0277308, and TY52156 were synthesized by Actelion Pharmaceuticals Ltd. (Switzerland). Cenerimod/ACT-334441 ((S)-3-(4-(5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)propane-1,2-diol) was synthesized by Actelion Pharmaceuticals Ltd.
(Switzerland). 16 
| GTPcS assay
| QPCR analysis
Tissues for Quantitative Polymerase Chain Reaction (QPCR) analysis were prepared from the upper (proximal) or lower (distal) trachea or the primary right bronchus from male Wistar rats (Harlan Laboratories Inc., Switzerland) and placed in RNAlater according to the manufacturer's instructions (Ambion, USA). Total RNA was extracted using
RNAeasy kits according to the manufacturer's instruction (Qiagen, Germany). Remaining genomic DNA was digested using the DNAse free kit (Ambion, USA). The quantity of RNA was analyzed using a Nanodrop spectrophotometer (Thermo Fisher, USA) and RNA quality was assessed using a Bioanalyzer 2100 (Agilent, USA). Total RNA was reverse transcribed with the high capacity cDNA archive kit according to the manufacturer's protocol (Applied Biosystems, USA).
The cDNA was preamplified according to the preamp kit with 14 cycles (Applied Biosystems, USA). S1P 1,2,3,4,5 receptor subtype mRNA expression was analyzed by quantitative PCR (QPCR) on a Biomark HD (Fluidigm, USA), using Taqman assays (Applied Biosystems, USA). Ppia-Rn00690933_m1and Pgk1-Rn00821429_g1 was used as reference genes and S1pr1 Rn02758712_s1, S1pr2-custom assay (For = GGAGAGACCAGGTGACCTCATC, probe = TGTCCCTC AGTGCCAC, Rev = ATGAGCCGTGGTCAGTTCCT), S1pr3-Rn027588 80_s1, S1pr4-Rn04108095_s1, and S1pr5-Rn00572952_s1 for mRNA detection. Results were calculated using a modified delta delta Ct method, 18 where an expression value of 1 reflects no detectable expression. Statistical comparison was performed using Student's unpaired t test (two-tailed). 
| Measurement of isometric force development
| Measurement of compound concentrations in plasma
After measurement of lymphocyte count, plasma was separated by centrifugation and stored at -20°C. Plasma samples were analyzed PIALI ET AL.
for cenerimod concentrations using liquid chromatography coupled to mass spectrometry. The performance of the bioanalytical assay was checked and documented by including quality-control samples.
| Blood pressure and heart rate measurements
After an acclimatization period of at least 7 days, male spontaneous hypertensive rats (SHRs) were weighed before surgery and pre- was used as an index of bronchoconstriction. 19 Each plethysmography chamber was calibrated before reading by rapid injection of 5 mL air.
One rat was placed per plethysmography chamber and lung function parameters were recorded for 120 minutes for baseline assessment.
Cenerimod, FTY720 or vehicle (methylcellulose 0.25%, containing 0.05% Tween 80) was administered orally at indicated doses and respiration parameters were measured for 6 hours after administration in the plethysmograph. Áday -1 cenerimod starting on day 0 ("preventive"). Alternatively, cenerimod dosing was started at day 14 ("thera- (Table 1) . Cenerimod was a highly potent (EC 50 = 1 nM) and selective S1P 1 receptor agonist, with a 16-fold higher potency on the S1P 1 receptor compared to the natural ligand S1P and similar maximal effect. In contrast to S1P and pFTY720, cenerimod displayed no detectable agonist activity on the S1P 2 receptor up to the highest tested concentration (10 lmolÁL -1 ), which was confirmed in cellular assays ( Figure S1 ).
| Statistical analysis
Cenerimod was at least 2000-fold less active at the S1P 3 receptor ). Cenerimod also showed high potency on rat and mouse S1P 1 receptors and pronounced selectivity over S1P 3 receptors (Table S1 ). The data demonstrate that cenerimod is a selective S1P 1 receptor modulator that exhibits a pronounced selectivity over the S1P 2 , S1P 3 , and S1P 4 receptor subtypes.
Next, the activity of cenerimod on intracellular signaling was studied. It was compared to that of S1P and pFTY720, using (
S)-
GTPcS and cellular Ca 2+ signaling assays in human primary umbilical vein endothelial cells (HUVEC), which naturally and predominantly express high S1P 1 receptor levels ( Figure S2 ). 22 As shown in Table 2 , cenerimod and pFTY720 were highly potent S1P receptor agonists in ( 35 S)-GTPcS assays using HUVEC cell membrane preparations and S1P was less potent. However, whereas S1P and pFTY720 pre- T A B L E 1 In vitro potency and maximal effect of cenerimod, pFTY720 and S1P on the S1P receptor family ) did not contract rat mesenteric arteries, whereas pFTY720 caused a concentration-dependent contraction, which was statistically significant at 1 nM concentration and above (Figure 2 ).
The in vivo effects of FTY720 and cenerimod on blood pressure were investigated in conscious SHR, using single oral doses of FTY720 (3 mgÁkg -1 ) or cenerimod (30 mgÁkg -1 ). These doses were ten times higher than the minimal dose that was required by both compounds to induce maximal lymphocyte reduction over 24 hours. 21 Mean arterial blood pressure (MAP) was similar in all experimental groups at baseline. Within a 48 hours observation period, oral administration of FTY720 increased MAP by 12 AE 2 mmHg, whereas cenerimod moderately decreased MAP by 9 AE 3 mmHg ( Figure 3A and B). Cenerimod showed no effect on heart rate (HR), whereas FTY720 slightly decreased HR by 26 AE 8 bpm.
| Cenerimod caused no bronchoconstriction ex vivo and in vivo
As it is known that the nonselective S1P receptor modulator FTY720 induces bronchoconstriction in animals and humans, 4, 26 we assessed the potential of cenerimod to induce bronchoconstriction ex vivo and in vivo. We first determined the mRNA expression levels of all S1P 1-5 receptor subtypes in rings from the upper rat trachea, lower rat trachea and right rat bronchus by using quantitative PCR ( Figure 4A ). Moderate S1P 1 and S1P 2 receptor mRNA expression T A B L E 2 Potency and maximal effect of cenerimod, pFTY720 and S1P in primary human endothelial cells were measured in conscious spontaneous hypertensive rats using telemetry. Statistical analysis was performed using a paired Student's t-test 24 hours before vs 24 to 30 hours after the treatment with *P ≤ .05, **P ≤ .01, ***P ≤ .001
was observed in all sections, with a slightly higher S1P 1 receptor expression in bronchi than in upper trachea. In contrast, S1P 3 receptor expression was moderate in the upper trachea but its abundance significantly increased almost threefold toward the lower trachea and almost fourfold in bronchi. Very low expression of the S1P 4 and S1P 5 receptor subtypes was detected in upper and lower trachea or bronchi. Consistent with this expression pattern, we observed S1P-induced lower rat trachea constriction ( Figure 4B ) that was inhibited by the selective S1P 1 receptor antagonist TASP0277308 25 and the selective S1P 3 receptor antagonist TY52156. 7 The S1P-induced constriction was fully abolished in absence of extracellular Ca 2+ .
Next, the effects of cenerimod and pFTY720 were evaluated in isolated rat trachea constriction experiments using upper and lower trachea segments and in bronchi. A complete lack of response was observed with cenerimod in the upper and lower trachea even at the highest tested concentration (10 lmolÁL . This concentration is at least 70-times higher than the minimal concentration needed to maintain maximal reduction of lymphocyte counts in rats (60 ngÁmL -1 , see below).
| Cenerimod reversibly reduced blood lymphocyte counts
Cenerimod caused a dose-dependent reduction in the number of circulating lymphocytes in rats, with a plateau reached after a single oral dose of 1 mgÁkg -1 . Blood lymphocyte counts decreased from 7900 AE 690 to 2900 AE 370 lymphocytes/lL, corresponding to a decrease of 63 AE 4%; P ˂ .001 ( Figure 7 ). The duration of lymphocyte count reduction was also dose-dependent. At 1 mgÁkg -1 , the lymphocyte count returned to predose levels within 48 hours, whereas at 3 mgÁkg -1 the blood lymphocyte count was still reduced by more than 40% at 48 hours. At a dose of 10 mgÁkg 3.5 | Cenerimod-attenuated disease in the mouse
EAE model
Cenerimod was studied in MOG peptide-induced, monophasic and chronic EAE model in C57BL/6 mice. 27 A clear increase in Mice that were treated with cenerimod starting from the time of maximal disease severity, ie 14 days after MOG injection ("thera- receptor pathway activation, in addition to S1P receptor subtype selectivity, might thus lead to distinct pharmacological profiles of different selective S1P 1 receptor modulators. During the medicinal chemistry program leading to cenerimod, we screened compounds for their potential to cause vasoconstriction, using isometric force measurements on isolated rat mesenteric arteries, and bronchoconstriction, using isolated rat trachea, rat bronchi and isolated human bronchi. We demonstrate here that cenerimod, unlike pFTY720, neither constricted rat mesenteric arteries or rat trachea, nor human bronchi. The low ex vivo bronchoconstricting potential of cenerimod was confirmed in vivo at plasma concentrations that were almost 70-fold higher than the minimal concentration required to maintain maximal lymphocyte reduction. Previous studies had suggested that the bronchoconstricting activity in mice, and possibly also in rats, is due to S1P 3 receptor activation. However, we demonstrate here that rat airways display a complex regional expression pattern of different S1P receptor subtypes and that both S1P 1 and S1P 3 receptor activation can induce Ca 2+ signaling-dependent trachea constriction. It is thus conceivable that the interplay of several S1P receptor subtypes and distinct signaling pathways influence physiological airway responses. In support of this hypothesis, we show that the nonselective, Ca 2+ signaling S1P [1] [2] [3] [4] [5] receptor agonist pFTY720 induces pronounced bronchoconstriction ex vivo and in vivo, as reported previously, 36, 37 and in addition we now show that the selective, Ca 2+ signaling S1P 1 receptor agonist pamiselimod 23 also leads to bronchoconstriction.
We also investigated the potential of cenerimod to influence mean arterial blood pressure in vivo and found that at doses exceeding ten times the doses that are required to induce maximal reduction of circulating lymphocytes, cenerimod did not induce an increase in blood pressure, but rather a moderate reduction in mean arterial blood pressure. This was in contrast to FTY720, which showed a mean arterial blood pressure increase also at a dose that was approximately ten times above the dose that is required to induce maximal lymphocyte count reduction 21 (data not shown). Together, these data demonstrate that cenerimod, unlike FTY720, lacked vasoconstricting and bronchoconstricting potential in our test systems. Our data thus show that cenerimod has a particularly favorable profile ex vivo and in vivo, which might be attributed to the unique combination of S1P 1 receptor selectivity and S1P 1 receptor signaling bias .
EAE reproduces some, but not all, pathophysiological hallmarks of human RMS. However, the EAE model is suitable for the study of histopathological features, including inflammation, demyelination, and neurodegeneration. As such the model can instruct about the mechanism of action on immunopathogenesis much more than it can predict efficacy in humans. 4, 17 The pathobiological mechanisms of 
